Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study
Cerbone, L., Combarel, D., Geraud, A., Auclin, E., Foulon, S., Alves Costa Silva, C., Colomba, E., Carril, L., Derosa, L., Flippot, R., Mir, O., Khoudour, N., Blanchet, B., Escudier, B., Paci, A., Albiges, L.
Published in ESMO open (01.12.2021)
Published in ESMO open (01.12.2021)
Get full text
Journal Article
728P Primary resistance (PrR) versus acquired resistance (AcR) to immune checkpoint inhibitors (ICI) in first-line metastatic renal cell carcinoma (mRCC)
Guida, A., Costa Silva, C. Alves, Colomba-Blameble, E., Flippot, R., Salviat, F., Bracarda, S., Escudier, B., Albiges, L.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
1452MO Longitudinal analysis reveals gut microbiota shift during standard therapies in metastatic renal cell carcinoma (mRCC)
Alves Costa Silva, C., Piccinno, G., Cerbone, L., Iebba, V., Colomba, E., Flippot, R., C. Sow, Darik, I., Maltez Thomas, A., Naoun, N., Bernard-Tessier, A., Reni, A., Segata, N., Escudier, B., Zitvogel, L., Albiges, L., Derosa, L.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
743P Activity of systemic therapies after cabozantinib (CABO) in patients (pts) with metastatic renal cell carcinoma (mRCC)
Cerbone, L., Di Nunno, V., Carril, L., Benchimol-Zouari, A., Flippot, R., Alves Costa Silva, C., Colomba-Blameble, E., Guida, A., Derosa, L., Escudier, B., Albiges, L.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
SO-22 Gut microbiome composition as predictor of the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: A translational analysis of the AtezoTRIBE study
Marmorino, F., Piccinno, G., Rossini, D., Ghelardi, F., Murgioni, S., Salvatore, L., Nasca, V., Antoniotti, C., Daniel, F., Schietroma, F., Conca, V., Costa Silva, C. Alves, Tamburini, E., Tamberi, S., Passardi, A., Carullo, M., Antonuzzo, L., D'Onofrio, R., Zitvogel, L., Cremolini, C., Derosa, L.
Published in Annals of oncology (01.06.2023)
Published in Annals of oncology (01.06.2023)
Get full text
Journal Article
259MO A predictive score of cancer immunotherapy responses based on ecological analysis of gut microbiota
Derosa, L., Alves Costa Silva, C., Iebba, V., Routy, B., Reni, A., Audigier-Valette, C., Zalcman, G., Mazieres, J., Friard, S., Goldwasser, F., Moro-Sibilot, D., Scherpereel, A., Pegliasco, H., Martinez, S., Escudier, B., Planchard, D., Albiges, L., Besse, B., Barlesi, F., Zitvogel, L.
Published in Annals of oncology (01.11.2022)
Published in Annals of oncology (01.11.2022)
Get full text
Journal Article
1480P Baseline levels of proinflammatory cytokines according to body mass index (BMI) and BMI impact on clinical outcomes in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (NIVO) within the NIVOREN trial
Colomba, E., Carril Ajuria, L., Dalban, C., Derosa, L., Alves Costa Silva, C., Rassy, E., Negrier, S., Chevreau, C.M., Gravis Mescam, G., Oudard, S., Laguerre, B., Barthelemy, P., Gross Goupil, M., Geoffrois, L., Thiery-Vuillemin, A., Joly Lobbedez, F., Ladoire, S., Tantot, F., Escudier, B., Albiges, L.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
Weight loss is an underestimated adverse event with cabozantinib in patients with metastastic renal cell carcinoma (mRCC)
Colomba, E., Alves Costa Silva, C., Le Teuff, G., Benchimol-Zouari, A., Guida, A., Derosa, L., Raynard, B., Escudier, B., Albiges, L.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
965PWeight loss is an underestimated adverse event with cabozantinib in patients with metastastic renal cell carcinoma (mRCC)
Colomba, E, Alves Costa Silva, C, Le Teuff, G, Benchimol-Zouari, A, Guida, A, Derosa, L, Raynard, B, Escudier, B, Albiges, L
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
967PSkeletal muscle loss as an adverse event during cabozantinib treatment in patients with metastatic renal cell carcinoma
Alves Costa Silva, C, Afonso, D, Colomba, E, Le Teuff, G, Derosa, L, Raynard, B, Guida, A, Benchimol-Zouari, A, Escudier, B, Bidault, F, Albiges, L
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
967P - Skeletal muscle loss as an adverse event during cabozantinib treatment in patients with metastatic renal cell carcinoma
Alves Costa Silva, C., Afonso, D., Colomba, E., Le Teuff, G., Derosa, L., Raynard, B., Guida, A., Benchimol-Zouari, A., Escudier, B., Bidault, F., Albiges, L.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
965P - Weight loss is an underestimated adverse event with cabozantinib in patients with metastastic renal cell carcinoma (mRCC)
Colomba, E., Alves Costa Silva, C., Le Teuff, G., Benchimol-Zouari, A., Guida, A., Derosa, L., Raynard, B., Escudier, B., Albiges, L.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
Skeletal muscle loss as an adverse event during cabozantinib treatment in patients with metastatic renal cell carcinoma
Alves Costa Silva, C., Afonso, D., Colomba, E., Le Teuff, G., Derosa, L., Raynard, B., Guida, A., Benchimol-Zouari, A., Escudier, B., Bidault, F., Albiges, L.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
697P Impact of β-blockers (BB) on outcomes of metastatic renal cell carcinoma (mRCC) patients treated with nivolumab (N)
Alves Costa Silva, C., Derosa, L., Dalban, C., Colomba, E., Negrier, S., Chevreau, C.M., Gravis, G., Oudard, S.M., Laguerre, B., Barthelemy, P., Borchiellini, D., Gross-Goupil, M., Geoffrois, L., Rolland, F., Thiery-Vuillemin, A., Joly, F., Ladoire, S., Tantot, F., Escudier, B., Albiges, L.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
657MO Antibiotic (ATB) therapy and outcome from nivolumab (N) in metastatic renal cell carcinoma (mRCC) patients (pts): Results of the GETUG-AFU 26 NIVOREN multicentric phase II study
Derosa, L., Alves Costa Silva, C., Dalban, C., Colomba, E., Negrier, S., Chevreau, C.M., Gravis, G., Oudard, S.M., Laguerre, B., Barthelemy, P., Borchiellini, D., Gross-Goupil, M., Geoffrois, L., Rolland, F., Thiery-Vuillemin, A., Joly, F., Ladoire, S., Tantot, F., Escudier, B., Albiges, L.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
974P - Prior tyrosine kinase inhibitors (TKI) and antibiotics (ATB) use are associated with distinct gut microbiota ‘guilds’ in renal cell carcinoma (RCC) patients
Iebba, V., Albiges, L., Alla, L., Colomba, E., Alves Costa Silva, C., Pons, N., Baciarello, G., Le Chatelier, E., Fizazi, K., Routy, B., Escudier, B., Zitvogel, L., Derosa, L.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
Prior tyrosine kinase inhibitors (TKI) and antibiotics (ATB) use are associated with distinct gut microbiota ‘guilds’ in renal cell carcinoma (RCC) patients
Iebba, V., Albiges, L., Alla, L., Colomba, E., Alves Costa Silva, C., Pons, N., Baciarello, G., Le Chatelier, E., Fizazi, K., Routy, B., Escudier, B., Zitvogel, L., Derosa, L.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
974PPrior tyrosine kinase inhibitors (TKI) and antibiotics (ATB) use are associated with distinct gut microbiota ‘guilds’ in renal cell carcinoma (RCC) patients
Iebba, V, Albiges, L, Alla, L, Colomba, E, Alves Costa Silva, C, Pons, N, Baciarello, G, Le Chatelier, E, Fizazi, K, Routy, B, Escudier, B, Zitvogel, L, Derosa, L
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses
Liu, Peng, Zhao, Liwei, Ferrere, Gladys, Alves-Costa-Silva, Carolina, Ly, Pierre, Wu, Qi, Tian, Ai-Ling, Derosa, Lisa, Zitvogel, Laurence, Kepp, Oliver, Kroemer, Guido
Published in Oncoimmunology (01.01.2020)
Published in Oncoimmunology (01.01.2020)
Get full text
Journal Article